-
OPEC+ hikes oil production by more than expected following outbreak of Iran war
-
Goggia tightens grip on World Cup super-G with victory in Andorra
-
Belgium seizes Russian 'shadow fleet' tanker
-
Raza steers Zimbabwe to 153-7 against South Africa
-
Kerr on target as Australia make winning start to Women's Asian Cup
-
Marquez says 'unlucky' to retire from MotoGP season opener
-
9 killed in pro-Iran protest at US consulate in Pakistan's Karachi
-
Green clinches Singapore title with help from caddie husband
-
More flights cancelled as Iran conflict shuts Mideast hubs
-
'One Battle After Another' wins top producer award before Oscars
-
Iran vows revenge for slain supreme leader despite Trump threat
-
Flights of fancy at Bottega Veneta with shimmering, tactile collection
-
World Cup marks 100-day countdown amid political upheaval
-
Bezzecchi wins MotoGP opener as Marquez retires
-
Pro-Iran protesters try to storm US missions in Pakistan, Iraq
-
8 killed in pro-Iran protest at US consulate in Pakistan's Karachi
-
Latest developments after US, Israeli strikes kill Iran's Khamenei
-
Before dawn, ancient drum rite wakes Istanbul faithful to fast
-
Music, mourning as Iran's Khamenei is killed
-
Pakistan cricket's lack of T20 evolution exposed by World Cup exit
-
Cobolli downs Tiafoe to claim Mexican Open
-
Takele defends Tokyo Marathon title after sprint finish
-
Hollywood's finest gather for guild's Actor Awards
-
Iran prepare for Women's Asian Cup as bombs drop on homeland
-
Doncic shines as Lakers cruise past depleted Warriors
-
3D tool Unreal Engine makes real impact in creative industries
-
OPEC+ mulls oil production increase in shadow of war
-
Putin, Russia's eternal leader defined by war and power
-
Explosion, gunfire as Afghan forces shoot at aircraft over Kabul
-
Iranians across North America rally for -- and against -- strikes
-
Shakespeare would have shunned streaming, 'Hamnet' team says
-
Will Oscars be 17th time lucky for songwriter Diane Warren?
-
Sympathy for the bedeviled: the likable conspiracy theorist of 'Bugonia'
-
Texas port humming as Trump ramps up Venezuela oil
-
76ers' center Embiid to miss at least three games with oblique strain
-
US, Israel defend strikes at UN as Iran alleges 'war crime'
-
Brumbies' 'mental resolve' keeps them unbeaten in Super Rugby
-
Iran attacks rock Dubai's Palm, Burj Al Arab, airport
-
JP Anderson Signs Landmark MOU with Vaama Village to Advance Rare Earth Mineral Development in Bonthe District
-
Iran leader Khamenei killed in massive US and Israeli attack, Trump says
-
UK pop-soul star Olivia Dean sweeps Brit Awards
-
Iranians across North America take to the streets for - and against - strikes
-
'Turning point' as Crusaders notch first Super Rugby win
-
White House releases photos of Trump, Vance during Iran ops
-
PSG win to extend lead over Lens at top of Ligue 1
-
Barca's Yamal nets hat-trick in Villarreal romp, Atletico go third
-
Trump says Khamenei is dead after Israel, US attack Iran
-
Iran's Khamenei: ruthless revolutionary atop Islamic republic
-
Inter continue Scudetto march after Champions League humbling
-
Questions cloud Trump's case for war against Iran
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."
"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."
AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
[email protected]
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
L.Harper--AMWN